SCHEMBL967161

SCHEMBL967161

O=C(O)C1C2CCC1CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.48
TDP1 Q9NUW8 3/20 0.48
KDM4E B2RXH2 2/20 0.48
LMNA P02545 2/20 0.48
PMP22 Q01453 2/20 0.48
TSHR P16473 2/20 0.48
APEX1 P27695 1/20 0.48
GMNN O75496 1/20 0.48
TFPI2 P48307 1/20 0.48
TP53 P04637 1/20 0.48
NFKB1 P19838 1/20 0.48
THPO P40225 1/20 0.48
GRM1 Q13255 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.36
GRM2 Q14416 5/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4968055 0.93 POLB (0.48) POLBTDP1KDM4ELMNAPMP22
SCHEMBL12226905 0.93 POLB (0.48) POLBTDP1KDM4ELMNAPMP22
SCHEMBL16909909 0.93 POLB (0.48) POLBTDP1KDM4ELMNAPMP22
SCHEMBL1664043 0.93 POLB (0.48) POLBTDP1KDM4ELMNAPMP22
SCHEMBL4686502 0.91 POLB (0.42) POLBTDP1KDM4ELMNAPMP22
SCHEMBL29953921 0.87
SCHEMBL850229 0.87 POLB (0.43) POLBTDP1KDM4ELMNAPMP22
SCHEMBL893248 0.84 POLB (0.42) POLBTDP1KDM4ELMNAPMP22
SCHEMBL15172745 0.82 POLB (0.46) POLBTDP1KDM4ELMNAPMP22
SCHEMBL23698034 0.80 LMNA (0.52) POLBTDP1KDM4ELMNAPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598927-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-08-13 EP disclosed
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2025-05-29 US disclosed
WO-2025054368-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NICO THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed
EP-4486722-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Nico Therapeutics, Inc. (US) 2025-01-08 EP disclosed
CN-119137101-A Compounds, compositions, and methods 尼科治疗有限公司 2024-12-13 CN disclosed
WO-2024077273-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-04-11 WO disclosed
US-11829068-B2 Resist composition, method of forming resist pattern, compound, and resin TOKYO OHKA KOGYO CO., LTD. (JP) 2023-11-28 US disclosed
WO-2023168298-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2023-09-07 WO disclosed
US-11709425-B2 Resist composition and method of forming resist pattern TOKYO OHKA KOGYO CO., LTD. (JP) 2023-07-25 US disclosed
US-11667605-B2 Resist composition, method of forming resist pattern, compound, acid generator, and method of producing compound TOKYO OHKA KOGYO CO., LTD. (JP) 2023-06-06 US disclosed
US-7179813-B2 Bicyclic indolyl derivatives and methods for their use as serotonergic agents WYETH (US) 2007-02-20 US disclosed
EP-1644355-A1 BICYCLIC INDOLYL DERIVATIVES AND METHODS OF THEIR USE AS SEROTONERGIC AGENTS Wyeth (US) 2006-04-12 EP disclosed
US-20050124630-A1 Bicyclic indolyl derivatives and methods for their use as serotonergic agents WYETH (US) 2005-06-09 US disclosed
WO-2004111035-A1 BICYCLIC INDOLYL DERIVATIVES AND METHODS OF THEIR USE AS SEROTONERGIC AGENTS WYETH (US) 2004-12-23 WO disclosed
US-6468998-B1 ANTAGONIZE SEROTONIN 2 RECEPTORS, SUPPRESS PLATELET AGGREGATION, IMPROVE PERIPHERAL CIRCULATION AND PROMOTE LACHRYMATION MITSUBISHI PHARMA CORPORATION (JP) 2002-10-22 US disclosed
CN-1332726-A Pyrrolidine compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2002-01-23 CN disclosed
EP-1125922-A1 PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF Welfide Corporation (JP) 2001-08-22 EP disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 EP disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 US disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11709425-B2 Resist composition and method of forming resist pattern RER1, RRS1, RXFP4 POLB 2124/4885TDP1 3476/4885KDM4E 2379/4885
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SARM1, SARS1, TIAM1 POLB 3077/4885TDP1 356/4885KDM4E 3128/4885
US-20050124630-A1 Bicyclic indolyl derivatives and methods for their use as serotonergic agents HTR4, HTR3A, TPH1 POLB 485/4885TDP1 864/4885KDM4E 3408/4885
US-11667605-B2 Resist composition, method of forming resist pattern, compound, acid generator, and method of producing compound RB1, RBBP5, RRM2B POLB 189/4885TDP1 4104/4885KDM4E 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.